Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.

WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations

Open access

Abstract

Inhibition of WEE1, a key regulator of the G2/M checkpoint of the cell cycle, induces apoptosis by initiating mitosis without repairing DNA damage. However, the effects of WEE1 inhibitors on the tumor immune microenvironment in colorectal cancer (CRC) remain unclear. Here, we investigated the association between WEE1 expression and CRC clinicopathological features using surgically resected CRC specimens and assessed the antitumor effects of a WEE1 inhibitor using CRC cell lines and orthotopic transplantation mouse models. WEE1 expression was not correlated with the clinicopathological features of CRC. The WEE1 inhibitor suppressed cell proliferation in a concentration-dependent manner in all CRC cell lines. It also increased the percentage of cells in the G2/M phase and apoptotic cells, especially in cell lines with p53 mutations, but did not alter these cell percentages in most p53 wild-type cell lines. In the orthotopic mouse model of CRC, tumor volume was significantly reduced in the WEE1 inhibitor-treated group compared to that in the control group. RNA sequencing and immunohistochemistry analyses of mouse tumors revealed that treatment with the WEE1 inhibitor activated tumor immunity and suppressed stromal reactions. These results demonstrate the potential antitumor effects of WEE1 inhibitors in CRC, particularly in patients with p53 mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16183136

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Association of WEE1 expression with the clinicopathological features and prognosis of CRC. (a) Immunohistochemical staining of WEE1 in surgical CRC specimens (100× magnification). Based on the staining intensity, the cells were classified as strong, moderate, weak, and negative, with strong and moderate being classified as the WEE1-positive group and weak and negative as the WEE1-negative group. (b) Immunohistochemical staining of p53 in surgical CRC specimens (100× magnification). Based on the distribution of immunostained positive cells, the cells were classified as diffuse strong, nested, negative, mosaic, sporadic, and diffuse weak, with diffuse strong, nested, and negative being classified as the p53 mutations and mosaic, sporadic, and diffuse weak as p53 wild types. (c) Database analysis based on the UCSC cancer genomic browser relationship between WEE1 expression and prognosis (overall survival rate) in CRC (GDC, The Cancer Genome Atlas (TCGA), Colon Adenocarcinoma (COAD) n = 487). (d) Association between WEE1 expression and prognosis (overall survival rate) in 152 patients with surgically resected CRC at our hospital. (e) Comparison of the overall survival rates of patients (n = 152) who underwent surgery for CRC classified by WEE1 expression and KRAS mutation status. Log-rank test *: p < 0.05, n.s.: not significant.
Figure 1 Association of WEE1 expression with the clinicopathological features and prognosis of CRC. (a) Immunohistochemical staining of WEE1 in surgical CRC specimens (100× magnification). Based on the staining intensity, the cells were classified as strong, moderate, weak, and negative, with strong and moderate being classified as the WEE1-positive group and weak and negative as the WEE1-negative group. (b) Immunohistochemical staining of p53 in surgical CRC specimens (100× magnification). Based on the distribution of immunostained positive cells, the cells were classified as diffuse strong, nested, negative, mosaic, sporadic, and diffuse weak, with diffuse strong, nested, and negative being classified as the p53 mutations and mosaic, sporadic, and diffuse weak as p53 wild types. (c) Database analysis based on the UCSC cancer genomic browser relationship between WEE1 expression and prognosis (overall survival rate) in CRC (GDC, The Cancer Genome Atlas (TCGA), Colon Adenocarcinoma (COAD) n = 487). (d) Association between WEE1 expression and prognosis (overall survival rate) in 152 patients with surgically resected CRC at our hospital. (e) Comparison of the overall survival rates of patients (n = 152) who underwent surgery for CRC classified by WEE1 expression and KRAS mutation status. Log-rank test *: p < 0.05, n.s.: not significant.CC BY · PubMed Central
Figure 2 Quantification of WEE1 expression in CRC cell lines and effect of WEE1 inhibitor on cell proliferation. (a) Relative expression levels of WEE1 in various CRC cell lines measured using real-time PCR, where its expression level in normal colonic mucosa was set as 1. (b) Growth curves of various CRC cell lines after exposure to various concentrations of the WEE1 inhibitor, adavosertib (200, 500, and 1000 nM), and untreated cells (control). The mean values are plotted. One-way ANOVA followed by Dunnett’s post hoc test, *: p < 0.05, **: p < 0.01, ***: p < 0.001.
Figure 2 Quantification of WEE1 expression in CRC cell lines and effect of WEE1 inhibitor on cell proliferation. (a) Relative expression levels of WEE1 in various CRC cell lines measured using real-time PCR, where its expression level in normal colonic mucosa was set as 1. (b) Growth curves of various CRC cell lines after exposure to various concentrations of the WEE1 inhibitor, adavosertib (200, 500, and 1000 nM), and untreated cells (control). The mean values are plotted. One-way ANOVA followed by Dunnett’s post hoc test, *: p < 0.05, **: p < 0.01, ***: p < 0.001.CC BY · PubMed Central
Figure 3 Effects of the WEE1 inhibitor on cell cycle and apoptosis induction in CRC cell lines. (a) Changes over time in the percentage of cells in the G1, S, and G2/M phases of the cell cycle as measured by cell cycle analysis in untreated (0 h) and various adavosertib-treated (1000 nM) CRC cell lines (at 4, 12, and 24 h). Comparison of percentage of apoptotic cells before (0 h) and 24 h after addition of adavosertib. *: p < 0.05, n.s.: not significant. (b) Changes over time in the percentage of apoptotic, viable, and necrotic cells in various untreated (0 h) and adavosertib-treated colon cancer cell lines. The cell lines were treated with 1000 nM adavosertib, and the analysis was performed 6, 24, and 48 h after treatment. Comparison of percentage of apoptotic cells before (0 h) and 48 h after the addition of adavosertib. *: p < 0.05, n.s.: not significant.
Figure 3 Effects of the WEE1 inhibitor on cell cycle and apoptosis induction in CRC cell lines. (a) Changes over time in the percentage of cells in the G1, S, and G2/M phases of the cell cycle as measured by cell cycle analysis in untreated (0 h) and various adavosertib-treated (1000 nM) CRC cell lines (at 4, 12, and 24 h). Comparison of percentage of apoptotic cells before (0 h) and 24 h after addition of adavosertib. *: p < 0.05, n.s.: not significant. (b) Changes over time in the percentage of apoptotic, viable, and necrotic cells in various untreated (0 h) and adavosertib-treated colon cancer cell lines. The cell lines were treated with 1000 nM adavosertib, and the analysis was performed 6, 24, and 48 h after treatment. Comparison of percentage of apoptotic cells before (0 h) and 48 h after the addition of adavosertib. *: p < 0.05, n.s.: not significant.CC BY · PubMed Central
Figure 4 Effects of the WEE1 inhibitor, adavosertib, on tumor volume in an orthotopic transplanted mouse model of CRC. (a) Orthotopic transplanted mouse model of CRC using MC38: transplant design and treatment schedule. n = 5, control group; n = 4, treatment group. (b) Macroscopic images of mouse tumors obtained following euthanasia on day 35 post-transplantation. (c) Comparison of tumor volume between control and treatment groups. (d) Orthotopic transplanted mouse model of CRC using CT26: transplant design and treatment schedule. n = 6, control group; n = 6, treatment group. (e) Macroscopic images of mouse tumors obtained following euthanasia on day 24 post-transplantation. (f) Comparison of tumor volume between control and treatment groups. Welch’s t-test, **: p < 0.01, n.s.: not significant.
Figure 4 Effects of the WEE1 inhibitor, adavosertib, on tumor volume in an orthotopic transplanted mouse model of CRC. (a) Orthotopic transplanted mouse model of CRC using MC38: transplant design and treatment schedule. n = 5, control group; n = 4, treatment group. (b) Macroscopic images of mouse tumors obtained following euthanasia on day 35 post-transplantation. (c) Comparison of tumor volume between control and treatment groups. (d) Orthotopic transplanted mouse model of CRC using CT26: transplant design and treatment schedule. n = 6, control group; n = 6, treatment group. (e) Macroscopic images of mouse tumors obtained following euthanasia on day 24 post-transplantation. (f) Comparison of tumor volume between control and treatment groups. Welch’s t-test, **: p < 0.01, n.s.: not significant.CC BY · PubMed Central
Figure 5 Evaluation of transplanted tumor specimens from a mouse model of CRC using MC38 by immunohistochemical staining. (a–c) Fluorescence immunostaining (200× magnification) of (a) CD8, (b) CD4, and (c) FoxP3. (d) Fluorescence immunostaining of PD-L1 (200× magnification). PD-L1: red; 4′,6-diamidino-2-phenylindole (DAPI): blue. The area around DAPI is stained because PD-L1 is expressed on the cell membrane. (e) Comparison of the number of CD8, CD4, and FoxP3-positive cells in the control and treatment groups. (f) Ki-67 immunostaining (200× magnification); (g) TUNEL staining (200× magnification). (h) Comparison of Ki-67 labeling index and percentage of TUNEL staining-positive cells between the control and treatment groups. Welch’s t-test, *: p < 0.05, n.s.: not significant, PD-L1: programmed cell death ligand 1; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling.
Figure 5 Evaluation of transplanted tumor specimens from a mouse model of CRC using MC38 by immunohistochemical staining. (a–c) Fluorescence immunostaining (200× magnification) of (a) CD8, (b) CD4, and (c) FoxP3. (d) Fluorescence immunostaining of PD-L1 (200× magnification). PD-L1: red; 4′,6-diamidino-2-phenylindole (DAPI): blue. The area around DAPI is stained because PD-L1 is expressed on the cell membrane. (e) Comparison of the number of CD8, CD4, and FoxP3-positive cells in the control and treatment groups. (f) Ki-67 immunostaining (200× magnification); (g) TUNEL staining (200× magnification). (h) Comparison of Ki-67 labeling index and percentage of TUNEL staining-positive cells between the control and treatment groups. Welch’s t-test, *: p < 0.05, n.s.: not significant, PD-L1: programmed cell death ligand 1; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling.CC BY · PubMed Central
Figure 6 Evaluation of the gene expression profiles in transplanted tumors using RNA sequencing. (a) Statistics of differentially expressed genes (DEGs; p < 0.05 and fold change > 2). (b) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. (c) Gene Ontology (GO) enrichment analysis. (d) Gene Set Enrichment Analysis (GSEA) in orthotopically transplanted tumors treated with or without WEE1 inhibitor. NES: normalized enrichment score.
Figure 6 Evaluation of the gene expression profiles in transplanted tumors using RNA sequencing. (a) Statistics of differentially expressed genes (DEGs; p < 0.05 and fold change > 2). (b) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. (c) Gene Ontology (GO) enrichment analysis. (d) Gene Set Enrichment Analysis (GSEA) in orthotopically transplanted tumors treated with or without WEE1 inhibitor. NES: normalized enrichment score.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Yokota, 2016, Evaluation of p53 Protein Overexpression by Immunohistochemistry―Study based on Gene Mutation Analysis, Niigata Igakukai Zassi, 130, 109

Cited by

See all 14

Metadata

Authors
Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S.
Affiliations
Hiroshima University Hospital (JP)
Corresponding author
Yuge, Ryo
Venue
Cancers
Publisher
MDPI AG
Published
2024-09-12
Volume
16
Issue
18
Pages
3136
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4402486551
Cited by
12
References
52
Citations by year
2026: 9 · 2025: 3
FWCI
2.05
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
WEE1 inhibitor, adavosertib, colorectal cancer, TP53 mutation, G2/M checkpoint, DNA damage-induced apoptosis, tumor immune microenvironment, antitumor immunity, tumor stroma, cell proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. https://app.cochat.ai/papers/10.3390/cancers16183136
The paper
Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024). WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. Cancers. https://doi.org/10.3390/cancers16183136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.